Premature Rupture of Membrane
16
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
PROMMO Trial: Oral Misoprostol vs IV Oxytocin
Dilapan-S®: A Multicenter US E-registry
Magnesium Sulphate in Premature Rupture of Membranes
Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices
Computerized Cardiotocography Monitoring of Fetuses With pPROM
HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor
Spanish Registry of Pregnant Women With COVID-19
Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections
Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL)
Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes
The Impact of Amniotic Fluid Index (AFI) on Maternal and Perinatal Outcomes in Pregnant Women With Preterm Premature Rupture of Membranes
Premature Rupture of Membranes at 34 to 37 Weeks' Gestation
Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)
The Use of Quantitative Pregnancy Test in Amniotic Fluid as a Diagnostic Tool for Rupture of Fetal Membranes
Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes